New functions of stromal proteases and their inhibitors in tumor progression.
Acquisition of invasive metastatic potential through protease expression is a key event in tumor progression. In carcinomas, the production of metalloproteinases and serine proteinases is regulated by a cross talk between stromal cells and cancer cells. Paradoxically, high rather than low levels of their inhibitors predict poor survival of patients suffering from a variety of cancers. Recent observations suggest a much more complex role of these inhibitors in tumor progression than expected initially.
Noel
A
A
Laboratory of Tumor and Developmental Biology, University of Liege, Tour de Pathologie, Liege, Belgium.
Albert
V
V
Bajou
K
K
Bisson
C
C
Devy
L
L
Frankenne
F
F
Maquoi
E
E
Masson
V
V
Sounni
N E
NE
Foidart
J M
JM
D018450:Disease Progression; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000502:physiology*; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology*; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000503:physiopathology; D010958:Plasminogen / Q000502:physiology; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012697:Serine Endopeptidases / Q000502:physiology*; D017154:Stromal Cells / Q000201:enzymology*
D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D010958:Plasminogen; D012697:Serine Endopeptidases; D020782:Matrix Metalloproteinases